Hippocratic AI is included on this list because of its prominence in the healthcare AI market — not because it is a clinical decision support tool. It is not one. The company has raised approximately $200 million in total funding, including a $120 million Series B led by Andreessen Horowitz in 2024, and builds patient-facing AI agents for non-diagnostic tasks: pre-visit screening, medication reminders, chronic care check-ins, and patient education.
These agents are designed to handle administrative and communication workflows that would otherwise require clinical staff, addressing the projected shortage of 124,000 physicians by 2034 as estimated by the AAMC. For health system administrators evaluating AI for operational efficiency, Hippocratic AI is relevant. For individual physicians looking for help with clinical reasoning, differential diagnosis, or evidence-based recommendations, it is not.
The enterprise-only pricing model means individual physicians cannot access the platform at all. We include Hippocratic AI because physicians will encounter it in conversations about healthcare AI, and they should understand what it does and does not do.